Literature DB >> 2488103

Acute and long-term hemodynamic effects of tiapamil at rest and during exercise in essential hypertension.

P Omvik1, P Lund-Johansen.   

Abstract

The first dose and long-term hemodynamic responses to tiapamil--an aralkylamine calcium-channel blocker--were studied both at rest and during exercise in 18 male patients (mean age, 45 years) with essential hypertension (EH). Blood pressure (BP) was measured intra-arterially, cardiac output (CO) was measured by dye dilution and heart rate (HR) was measured by electrocardiogram. One hour after the first oral dose of 600 mg tiapamil, mean arterial pressure (MAP) fell 14%. Total peripheral resistance (TPR) fell 21%, while HR and CO increased 7% and 11%, respectively. Thereafter the effects leveled off. After 11 months of chronic tiapamil therapy (mean dose 980 mg per day), MAP was reduced 11% at rest sitting. The reduction in BP was associated with a modest reduction in TPR. Similar responses were seen at rest supine and during 100-W bicycle exercise. A small reduction was seen in HR while CO was preserved. In conclusion, tiapamil exerts a moderate antihypertensive effect, both at rest and during exercise, through reduction of TPR without a fall in heart pump function. The long-term hemodynamic changes are rather similar to those of verapamil.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2488103     DOI: 10.1007/bf01865510

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  20 in total

1.  A new Ca++ antagonist, Ro 11-1781, and its metabolites. Synthesis and physicochemical properties.

Authors:  H Ramuz
Journal:  Arzneimittelforschung       Date:  1978

2.  Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension.

Authors:  P Lund-Johansen; P Omvik
Journal:  J Hypertens Suppl       Date:  1984-12

3.  Overview on the pharmacological and toxicological characterization of the calcium antagonist tiapamil.

Authors:  G Haeusler; R Eigenmann; M Gerold; F Hefti; D Jovanovic; L Blaber; K Nakamura; S Thorens
Journal:  Cardiology       Date:  1982       Impact factor: 1.869

4.  [Initial experiences with the calcium antagonist tiapamil in the treatment of arterial hypertension].

Authors:  F Rhomberg; K Bachmann; H Bächtold; P Müller
Journal:  Schweiz Med Wochenschr       Date:  1983-12-10

5.  The 24-hour ambulatory blood pressure profile with verapamil.

Authors:  B A Gould; S Mann; H Kieso; V B Subramanian; E B Raftery
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

6.  Hemodynamic effects of verapamil in essential hypertension at rest and during exercise.

Authors:  P Lund-Johansen
Journal:  Acta Med Scand Suppl       Date:  1984

7.  Cardiovascular effects of verapamil in patients with essential hypertension.

Authors:  R E Schmieder; F H Messerli; G E Garavaglia; B D Nunez
Journal:  Circulation       Date:  1987-05       Impact factor: 29.690

8.  Haemodynamic effects of nifedipine in essential hypertension at rest and during exercise.

Authors:  P Lund-Johansen; P Omvik
Journal:  J Hypertens       Date:  1983-08       Impact factor: 4.844

Review 9.  Second-generation calcium antagonists: search for greater selectivity and versatility.

Authors:  B N Singh; S Baky; K Nademanee
Journal:  Am J Cardiol       Date:  1985-01-25       Impact factor: 2.778

10.  Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension.

Authors:  R B Devereux; D D Savage; I Sachs; J H Laragh
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

View more
  1 in total

1.  The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.